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Summary
Aging is accompanied by imbalanced bone remodeling, elevated osteocyte apoptosis, and 
decreased bone mass and mechanical properties; and improved pharmacologic approaches to 
counteract bone deterioration with aging are needed. We examined herein the effect of mefloquine, 
a drug used to treat malaria and systemic lupus erythematosus and shown to ameliorate bone loss 
in glucocorticoid-treated patients, on bone mass and mechanical properties in young and old mice. 
Young 3.5-month-old and old 21-month-old female C57BL/6 mice received daily injections of 
5mg/kg/day mefloquine for 14 days. Aging resulted in the expected changes in bone volume and 
mechanical properties. In old mice mefloquine administration reversed the lower vertebral 
cancellous bone volume and bone formation; and had modest effects on cortical bone volume, 
thickness, and moment of inertia. Mefloquine administration did not change the levels of the 
circulating bone formation markers P1NP or alkaline phosphatase, whereas levels of the resorption 
marker CTX showed trends towards increase with mefloquine treatment. In addition, and as 
expected, aging bones exhibited an accumulation of active caspase3-expressing osteocytes and 
higher expression of apoptosis-related genes compared to young mice, which were not altered by 
mefloquine administration at either age. In young animals, mefloquine induced higher periosteal 
bone formation, but lower endocortical bone formation. Further, osteoclast numbers were higher 
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on the endocortical bone surface and circulating CTX levels were increased, in mefloquine-
compared to vehicle-treated young mice. Consistent with this, addition of mefloquine to bone 
marrow cells isolated from young mice led to increased osteoclastic gene expression and a 
tendency towards increased osteoclast numbers in vitro. Taken together our findings identify the 
age and bone-site specific skeletal effects of mefloquine. Further, our results highlight a beneficial 
effect of mefloquine administration on vertebral cancellous bone mass in old animals, raising the 
possibility of using this pharmacologic inhibitor to preserve skeletal health with aging.
Keywords
cell/tissue signaling; osteoclast; aging; therapeutics
Introduction
A combination of intrinsic factors, including elevated oxidative stress, increased endogenous 
glucocorticoid action and low sex steroids [1], and reduced physical activity, lead to bone 
loss and increased risk of fractures with advanced age. This not only results in considerable 
morbidity, but also elevated mortality following, for example, hip fractures [2]. As the 
skeleton ages, there is an imbalance in bone remodeling with bone resorption prevailing over 
bone formation, resulting in a net loss of bone mass [3]. In addition, bone mechanical 
properties decrease with aging. Factors associated with aging, have opposite effects on 
osteoclasts and osteoblasts, resulting in increased differentiation/activity of the bone 
resorbing cells whereas bone forming cells exhibit increased apoptosis and reduced activity. 
Osteocyte apoptosis and empty lacunae are also increased with aging and their accumulation 
is associated with defective bone material properties [4, 5]. Further, osteoclasts accumulate 
in areas nearby apoptotic osteocytes, but not in the vicinity of empty lacunae, suggesting that 
dying osteocytes secrete factors that signal for osteoclast recruitment [6–11].
Mefloquine is a member of the quinine-derived family of drugs that also includes 
chloroquine and hydroxychloroquine, commonly used in patients to treat malaria and 
systemic lupus erythematosus [12]. As a group, the quinine-derived family of drugs are 
inhibitors of autophagy [13]. In addition, it has been shown that mefloquine inhibits 
membrane channels such as pannexin 1 (Panx1) [14, 15], L-type calcium channels [16], 
potassium channels [17], volume-regulated and calcium-activated chloride channels [18], 
ATP-sensitive potassium channels [19], and connexin channels [20]. Studies in patients have 
shown that hydroxychloroquine administration results in attenuated spinal bone loss when 
the drug is administered alongside glucocorticoids [21], an agent that induces bone loss and 
increases fragility [22]. Additionally, quinine-derived drugs increased spinal and hip bone 
mineral density in patients with systemic lupus erythematosus [23, 24]. Studies have shown 
that chloroquine reduces osteoclast numbers in young growing rodents and prevents 
overiectomy-induced bone loss in older, 8–9-month-old mice [25]. Whether this kind of 
drug alters the consequences of aging on the skeleton was heretofore unknown.
We hypothesized that by reducing osteoclast numbers mefloquine would ameliorate the 
deleterious skeletal effects of aging. To test this, we treated young and old mice with 
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mefloquine daily for 2 weeks. Unexpectedly, we found that short-term mefloquine 
administration did not decrease osteoclastogenesis in old mice and actually increased 
osteoclast number/activity in young mice. Further, in aged mice mefloquine increased 
vertebral cancellous bone formation and mass in a sclerostin-independent manner. In 
addition, our results suggest that mefloquine administration might prevent the consequences 
of aging on bone strength. These findings raise the possibility of using this pharmacologic 
inhibitor to improve the cancellous bone mass and strength with aging.
Materials and Methods
Mice and treatment
3.5-(young, n=8–9/group) and 21-month-old (old, n=10/group) C57BL/6 female mice were 
obtained from National Institute on Aging (NIA) and administered daily intraperitoneal 
injection of vehicle (1.5% ethanol) or 5mg/kg/day of mefloquine (BioBlocks Inc., San 
Diego, CA, USA, cat.# QU024-1) for 14 days [26]. Mice were assigned an ID number and 
the age and treatment were recorded in a database. Investigators performing endpoint 
measurements were only given the mouse IDs, thus blinded to treatment and age. Mice were 
randomized and assigned to each experimental group based on matching spinal BMD. 
Animals were sacrificed 4–6 hours after receiving the last injection. Mice (5/cage) were fed 
a regular diet (Envigo, Indianapolis, IN) and water ad libitum, and maintained on a 12h 
light/dark cycle. All experiments were carried out as planned, with no adverse effects 
resulting from treatments. The mice received intraperitoneal injections of calcein (30 mg/kg; 
Sigma-Aldrich, Saint Louis, MO, USA) and alizarin red (50 mg/kg; Sigma) 7 and 2 days 
before sacrifice, respectively, to allow for dynamic histomorphometric measurements [27].
Micro-computed tomography (μCT) analysis
Lumbar vertebrae (L4) and femora were dissected, cleaned of soft tissue and wrapped in 
PBS-soaked gauze and frozen at −20°C until imaging [28]. Bones were scanned using 50kV 
source, 120mA, 151milliseconds integration time, and 10μm voxel resolution on a μCT-35 
(Scanco Medical AG, Brüttisellen, Switzerland). Scans were reconstructed and analyzed 
using manufacturer software. The following parameters were obtained for the cancellous 
bone of the lumbar vertebrae: trabecular bone volume per total volume (BV/TV, %), 
trabecular number (Tb.N, mm-1), trabecular thickness (Tb.Th, mm), and trabecular spacing 
(Tb.Sp, mm). For cortical bone of the femoral diaphysis, the following parameters were 
obtained: bone area/total area (%), marrow cavity area (mm2), cortical thickness (mm), and 
polar moment of inertia (Ip, mm4). Nomenclature is reported in accordance with suggested 
guidelines for μCT [29].
Bone histomorphometry
Lumbar vertebrae (L1–L3) and femora and were dissected and fixed in 10% neutral buffered 
formalin [28]. Dynamic histomorphometric analysis of unstained methyl methacrylate 
embedded L1–L3 vertebra longitudinal sections, avoiding the primary spongiosa, and 
femoral mid-diaphysis cross-sections was performed using an epifluorescence microscope. 
Static histomorphometric analysis was performed on decalcified, paraffin-embedded femoral 
mid-diaphysis cross-sections (for osteoclasts) and undecalcified plastic-embedded L1–L3 
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vertebra longitudinal sections (for osteoclasts and osteoblasts). Sections were stained for 
TRAP/Toluidine blue and von Kossa/McNeal in order to visualize osteoclasts and 
osteoblasts, respectively. Histomorphometric analysis was performed using the 
OsteoMeasure high resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA). 
The terminology and units used are those recommended by the Histomorphometry 
Nomenclature Committee of the American Society for Bone and Mineral Research 
(ASBMR) [29].
Biomechanical testing
Three-point bending testing of the femoral mid-diaphysis was performed following 
previously published protocols [30]. Briefly, bones were thawed to room temperature, 
hydrated in 0.9% saline, and loaded to failure at 2mm/min with force versus displacement 
data collected at 10Hz using a servo-hydraulic test system (TestResources Inc., Shakopee, 
MN, USA). Femora were loaded to failure in an anterior–posterior direction with the upper 
contact area at the mid-diaphysis (50% total bone length) and the bottom contact points 
centered around this point and separated by 8mm. Whole bone mechanical properties (load, 
displacement, stiffness, energy) were derived from the load-displacement curves. Cross-
sectional moment of inertia and anterior–posterior diameter were determined by μCT and 
were used to calculate estimated material-level properties, as previously described [30].
Immunohistochemistry for active caspase-3
Decalcified, paraffin-embedded femoral mid-diaphysis cross-sections were deparaffinized, 
treated with 3% H2O2 to inhibit endogenous peroxidase activity, blocked and then incubated 
with rabbit monoclonal anti-active caspase-3 antibody (1:75; Thermo Fisher Scientific In., 
Rockford, IL, USA, cat.#PA5-23921)[31]. Sections were then incubated with anti-rabbit 
biotinylated secondary antibody followed by avidin conjugated peroxidase (Vectastain Elite 
ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA). Color was developed with a 
diaminobenzidine substrate chromogen system (Acros Organics, New Jersey, USA). Cells 
expressing the protein of interest are stained in brown, whereas negative cells are green-blue. 
Nonimmune IgG was used as a negative control. One section from each mouse at 400× 
magnification was evaluated.
RNA extraction and real-time PCR (qPCR)
Total RNA was isolated using TRIzol (Invitrogen, Grand Island, NY, USA), as previously 
published [32]. Reverse transcription was performed using a high-capacity cDNA kit 
(Applied Biosystems, Foster City, CA, USA). qPCR was performed using the Gene 
Expression Assay Mix TaqMan Universal Master Mix and an ABI 7900HT real-time PCR 
system. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used. Primers and probes were commercially available (Applied Biosystems, Foster City, 
CA, USA) or were designed using the Assay Design Center (Roche Applied Science, 
Indianapolis, IN, USA). Relative expression was calculated using the ΔCt method [33].
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Circulating bone markers
Blood was collected in vials containing the anti-coagulant BD SST by cheek bleeding after 4 
hours of fasting. Plasma was separated, aliquoted, and stored at −80°C until used [30]. 
Plasma N-terminal propeptide of type I procollagen (P1NP) (Immunodiagnostic Systems 
Inc., Fountain Hill, AZ, USA, cat.#AC-33F1) and C-telopeptide fragments (CTX) (RatLaps, 
Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, cat.#AC-06F1) were measured as 
described by the manufacturer. Alkaline phosphatase activity was assessed by a standard 
automated method using a Randox Daytona chemical analyzer (Randox Laboratories Ltd., 
Crumlin, United Kingdom).
Osteoclastogenesis assay
Non-adherent bone marrow cells (3×105 cells/cm2) were plated on a 24-well with 20ng/ml 
recombinant murine M-CSF and 80ng/ml recombinant murine soluble RANKL (PeproTech 
Inc., Rocky Hill, NJ, USA) with either 1mM of mefloquine or vehicle. Medium was 
changed every 2 days for 7 days [28]. The conditioned medium (CM) was collected at day 7 
to measure ATP concentration. Osteoclasts exhibiting 3 or more nuclei were enumerated 
after staining for TRAPase using a commercial kit (Sigma-Aldrich, Saint Louis, MO, USA, 
cat.#387A). Images were acquired using a Zeiss Axiovert 35 microscope equipped with a 
digital camera (Carl Zeiss, Thronwood, NY, USA). mRNA was isolated from parallel 
cultures and gene expression was measured by qPCR (Applied Biosystems, Foster City, CA, 
USA).
Protein extraction and sclerostin measurement
Whole protein extracts from bone were prepared as published [11, 34]. Sclerostin levels 
were measured using an ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA, 
cat.#MSST00) following the manufacturer instructions.
ATP staining
For ATP staining, cells were incubated with 100μM of quinacrine (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA, cat.#sc-204222) in PBS for 20 min at 37% and 5% 
CO2, rinsed twice with PBS. Images were immediately taken using a fluorescence 
microscope. Cells were then lysed and 10μl of each sample were mixed with 100μl of 
luciferin-luciferase reagent in a 96-well black clear-bottom microplate and luminescence 
was measured. Values are expressed as relative light units (RLU).
Statistical analysis
Data were analyzed by using SigmaPlot 13.0 (Systat Software Inc., San Jose, CA, USA). All 
values are reported as the mean ± standard deviation. Differences among samples were 
analyzed by two-way ANOVA, with post-hoc analysis using Tukey test or by t-test, as 
appropriate. Differences were considered significant when p ≤ 0.05.
Study approval
The protocols involving animal procedures were approved by the Institutional Animal Care 
and Use Committee of Indiana University School of Medicine.
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Results
Mefloquine administration reverses vertebral cancellous bone loss in old mice
Vertebral bone volume/tissue volume (BV/TV) was significantly lower in vehicle-treated old 
compared to young mice (Fig. 1). Mefloquine treatment reversed the low BV/TV in old mice 
through significant effects on trabecular thickness, without affecting young animals. 
Trabecular number was not altered by either age or treatment. The changes in vertebral 
cancellous bone were accompanied by corresponding changes in bone formation rate (Fig. 
2A). In old mice, bone formation was lower compared to young mice due to lower mineral 
apposition rate, whereas mineralizing surface, as well as osteoblast number were not 
changed (Fig. 2A and 2B). Mefloquine administration increased MAR and BFR in old mice 
(Fig. 2A). Further, osteoblast number was increased in both young and old animals treated 
with the drug (Fig. 2B), whereas the prevalence of apoptotic osteoblasts was not changed by 
administering mefloquine (not shown). On the other hand, osteoclast parameters were not 
changed with either age or pharmacologic treatment (Fig. 2C). This evidence suggests that 
increased vertebral cancellous bone in old mice treated with mefloquine is due to increased 
osteoblast activity.
Mefloquine shows tendencies towards improved mechanical properties but has minimal 
effects on the geometry of cortical bone in old mice
Microarchitecture analysis in the femoral mid-diaphysis of vehicle-treated old mice showed 
a reduction in cortical bone area/tissue area (BA/TA) and cortical thickness, while marrow 
cavity area, material density, moment of inertia, and tissue area (not shown) were higher 
when compared to young mice (Fig. 3). Mefloquine treatment induced a small but 
significant reduction in marrow cavity area and moment of inertia in old mice, without 
affecting cortical bone geometry in young animals.
Consistent with the alterations in femoral cortical bone architecture, skeletal aging had 
deleterious effects on the biomechanical properties of the femur as evidenced by decreased 
displacement to yield, yield stress, strain to yield, and resilience in vehicle-treated old mice 
(Table 1 and 2). Mefloquine administration differentially affected the mechanical properties 
in the two age groups. In young mice, mefloquine treatment had no effect on the mechanical 
or material properties, except for increasing toughness compared to vehicle-treated age-
matched mice. On the other hand, in old mice, mefloquine treatment showed a tendency to 
reverse several parameters back to the levels observed in young vehicle-treated mice. 
Specifically, the structural property displacement to yield and several material properties, 
yield stress, strain to yield, and resilience, were not different in old mefloquine-treated mice 
compared to young vehicle-treated animals by post hoc statistical analysis, although the 
increases in these parameters did not reach significance when comparing old mice treated 
with the vehicle versus the drug.
Mefloquine administration alters femoral mid-diaphysis cortical bone turnover in young 
animals, without affecting these parameters in old mice
Dynamic histomorphometry on the periosteal surface of the femoral mid-diaphysis revealed 
higher mineral apposition rate, mineralizing surface and bone formation rate in vehicle-
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treated old compared to young mice (Fig. 4A). On the other hand, mineralizing surface and 
bone formation rate were reduced (without changes in mineral apposition rate) on the 
endocortical surface in old mice. In old mice, mefloquine treatment had no effect on the 
bone formation parameters on either the periosteal or endocortical surface. On the other 
hand, pharmacological treatment in young mice resulted in increased bone formation 
parameters on the periosteal surface, whereas endocortical mineralizing surface and bone 
formation were reduced. Osteoclast number and surface on the endocortical bone were not 
changed by age, but were significantly increased with mefloquine treatment in young and 
not old mice (Fig. 4B).
No changes in the circulating markers of bone resorption or formation were detected in old 
compared to young mice, although a tendency towards increased in alkaline phosphatase 
was found in vehicle-treated old mice (p= 0.055) (Fig. 5A). Consistent with the increase in 
cortical osteoclasts observed in young treated animals, mefloquine administration increased 
the levels of the resorption marker C-terminal telopeptide (CTX) in the circulation of young, 
but not old mice. On the other hand, the levels of the bone formation markers procollagen I 
intact N-terminal (P1NP) and alkaline phosphatase (ALP) did not change with mefloquine 
administration. The lack of effect of mefloquine on circulating bone formation markers 
could be due to the fact that osteoblast activity was changed in some, but not all bone 
compartments.
Mefloquine treatment increased osteoclast differentiation in vitro
We next examined the effect of mefloquine in vitro and found that treatment of non-adherent 
bone marrow cells with the drug led to a tendency towards increased osteoclast number 
without changes in size; and a significant increase in the expression of TRAP and calcitonin 
receptor in the mature osteoclasts (Fig. 5A and B). Similar effects were obtained when 
mefloquine was removed from the media after 5 days of culture, but not when the drug was 
added 5 days after starting osteoclast differentiation (not shown), suggesting that mefloquine 
has an effect on osteoclast precursors and not in mature cells. However, we cannot exclude 
the possibility that mefloquine increases osteoclast differentiation by acting indirectly on 
stromal cells that might be present in the non-adherent bone marrow cell cultures.
Mefloquine has been shown to inhibit the opening of pannexin1 channels [14, 15, 26] and to 
prevent ATP release [35, 36]. Consistent with this, mature osteoclast cultures exhibited more 
intracellular ATP in the presence of mefloquine (Fig. 5C). The change in ATP levels was not 
associated with dysregulation of pannexin levels, as aging or mefloquine treatment did not 
alter Panx1 or 3 levels and Panx2 was only detected in some, but not all bone samples (not 
shown).
Mefloquine administration increases the prevalence of empty lacunae and reduces Sost 
levels in young but not old mice
In order to investigate the mechanism behind increased bone mass in old mefloquine-treated 
mice, levels of Sost/sclerostin, a potent bone formation inhibitor, were measured. Despite the 
increased mRNA levels of the Sost gene measured in the marrow-flushed tibia samples 
compared to vehicle-treated young mice, sclerostin expression was lower in vertebra bone 
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lysates of vehicle-treated old mice (Fig. 6A and B). These results are consistent with the 
increases in the total number of osteocytes, potentially expressing sclerostin, in the cortical 
bone of the femur, while a reduction in the total number of osteocytes was observed in 
vertebral cancellous bone of old compared to young vehicle-treated mice (Fig. 6C). 
Mefloquine treatment reduced Sost mRNA without affect sclerostin protein levels in young 
mice, and did not affect Sost/sclerostin expression in old animals. On the other hand, while 
osteocyte number was increased in the old mice, the proportion of apoptotic osteocytes, 
determined by active caspase-3 staining, and number of empty osteocyte lacunae was 
increased in old compared to young mice in both treatment groups (Fig. 6D). Further, 
mRNA levels of several apoptosis markers were increased in marrow-flushed tibia samples 
from the old animals (Fig. 6E). In old mice, mefloquine treatment did not alter osteocyte 
apoptosis or apoptotic gene expression in the cortical bone of the femoral mid-diaphysis, 
whereas in young mice a tendency towards increase in the number of caspase-3 positive 
osteocytes and a significant increase in the number of empty lacunae were observed with 
drug treatment. Our evidence suggests the possibility that the higher periosteal bone 
formation in femur of young mefloquine treated mice and old mice from both treatment 
groups, could be due to a local decrease in sclerostin levels in bone resulting from a decrease 
in the number of sclerostin-expressing osteocytes.
Discussion
In this study, we found that short-term administration of mefloquine, a quinine-derived drug, 
shown to ameliorate the adverse skeletal effects of glucocorticoids and lupus [21, 23, 24], 
differentially effects bone formation in a bone site and age-specific manner. In old mice, it 
increases vertebral cancellous bone formation leading to increases in cancellous bone mass. 
Whereas in young mice while it increases bone formation on the periosteal surface of the 
femoral mid-diaphysis, it decreases endocortical bone formation. In addition, we found that 
mefloquine increases the number of osteoclasts on the endocortical surface of the femur and 
the circulating CTX levels only in young animals. Further, bone mechanical properties 
showed tendencies towards increase following mefloquine administration in old, but not 
young mice.
The mechanism(s) by which mefloquine exerted these effects is not clear, as the drug is able 
to affect several channels. In particular, it has previously been shown that the drug blocks 
Panx1 channels in the nervous system [26] and acts on these channels with high sensitivity 
[14, 15]. Pannexins are a recently discovered class of single-membrane channel forming 
proteins that share similar topology with connexin channels, but do not form gap junctions 
[37]. This small family of integral membrane proteins consists of three members, Panx1, 
Panx2, and Panx3, with approximately 94% similarity between mice and humans [38]. 
Pannexins have a distinct pattern of expression. Panx1 is the most well-characterized and 
widely expressed pannexin family member [39]. Panx2 was originally believed to only be 
expressed in the nervous system, but has recently been found in other tissues [40], including 
osteoblasts in bone [41]. Panx3 is expressed in bone, teeth, and skin [39].
Panx1 channels open in apoptotic cells as a result of cleavage of the Panx1 auto-inhibitory 
domain by active caspase-3 [35, 36]. This leads to the release of ATP, which functions as a 
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“find-me” chemotactic signal for phagocytes. Thus, opening of Panx1 channels in apoptotic 
osteocytes could result in ATP release and osteoclast differentiation through direct actions 
on osteoclast precursors and indirectly by stimulating RANKL expression in 
osteoclastogenesis supporting cells [42, 43]. Consistent with this possibility, global deletion 
of Panx1 inhibited osteoclast recruitment in apoptotic osteocyte-containing bone regions 
where mechanically-induced microdamage had occurred [44]. However, in this study 
mefloquine treatment did not alter osteoclastogenesis in the old mice, and actually increased 
femur endocortical osteoclast number/surface in the young mice. This increase could result 
from direct effects of mefloquine on osteoclastic cells, as suggested by our in vitro findings 
demonstrating an increase in osteoclast differentiation in the presence of mefloquine. Unlike 
our findings on osteoclast differentiation, it was demonstrated that an analog, chloroquine, 
prevents osteoclastogenesis by suppressing canonical and non-canonical NF-κB signaling 
[25]. Furthermore, disruption for nuclear mitochondrial transcription factor A (Tfam) gene 
reduced intracellular ATP in osteoclasts and led to a decrease in osteoclast survival [45]. In 
our study, upon mefloquine treatment in vitro, osteoclasts accumulated intracellular ATP, 
which might have prolonged their lifespan. Future studies are needed to examine the role of 
ATP on mefloquine effects in osteoclasts.
In addition to pannexin, mefloquine can also inhibit other channels, such as cardiac L-type 
calcium channels [16] and potassium channels [17], volume-regulated and calcium-activated 
chloride channels in pulmonary artery endothelial cells [18], ATP-sensitive potassium 
channels in pancreatic β cells [19], and N2A neuroblastoma cell Cx36 channels (and Cx50, 
Cx43, Cx32, and Cx26 at higher concentrations) [20]. These inhibitory effects of mefloquine 
are exerted at concentrations between 1–100μM, with EC50 ranging between 0.3 and 3μM. 
While no side-by-side comparison for the different receptors in the same cell type have been 
reported, the effects of mefloquine on pannexin channels can be detected at concentrations 
of 10–100nM, suggesting high sensitivity of pannexin channels to mefloquine effects. 
Nevertheless, we cannot exclude the possibility that the beneficial effects of mefloquine on 
the skeleton are due to inhibition of channels other than pannexins. Future studies will be 
performed to identify the molecular target for the effects of mefloquine on the skeleton.
Our findings demonstrate that mefloquine administration results in bone compartment- as 
well as age-dependent changes in bone cell differentiation/activity, bone mass and 
mechanical properties. Thus, in old animals mefloquine increased vertebral cancellous bone 
formation, explaining the reversal of the decreased bone volume in the old mice, but did not 
alter femoral cortical bone turnover. On the other hand in young mice mefloquine did not 
alter vertebral cancellous bone turnover, but had opposite effects on periosteal (increases) 
and endocortical (decreases) bone formation, leading to no net change in femoral cortical 
thickness. It is possible that the different response in the bone compartments and old versus 
young mice is due to the short duration (2 weeks) of treatment and that, given enough time, 
all bones/animals will respond in a similar fashion. Further, we cannot exclude the 
possibility that the differences observed in cancellous versus cortical bone are due to the fact 
that the cancellous bone was analyzed in vertebral bone whereas the cortical bone was 
studied in femoral bone. In particular, it is possible that the difference in loading between the 
two bones influences the effect of aging and/or the drug. However, we have previously 
shown that similar effects can be seen in cancellous bone of the vertebra and the distal 
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femur, suggesting that the difference in responses are due to the difference in the 
compartment, rather than a difference in the loading of the bone [28, 30, 46].
Overall, we did not find any substantial changes in cortical bone structure following 2-week 
mefloquine administration, with only slight reductions in marrow cavity volume and 
moment of inertia, suggesting that the short-term administration of the drug was not enough 
to alter bone geometry. Nevertheless, we found that the drug showed tendencies towards 
increase, without reaching significance, on several bone biomechanical properties suggesting 
that bone quality might have improved in mice treated with mefloquine. Given the fact that 
mice were given the drug for only 2 weeks, it is possible that a longer duration of 
mefloquine administration may yield stronger effects on the structural and mechanical 
properties of the cortical bone in old mice. Further studies are needed to understand the basis 
of the improved mechanical properties.
Bone formation was increased in mice receiving mefloquine and, since mefloquine is known 
to be an inhibitor of several membrane channels, our evidence suggests that the target of 
mefloquine action is a repressor of osteoblast activity. Unlike our findings, a study by 
Boyce’s group [25] using chloroquine at the same dose as the one used by us, did not find 
alterations in bone formation in 6-week-old mice or in osteoblastic cells in vitro. An 
increased sensitivity to the drugs with aging or the fact that the study by Boyce’s group use a 
similar, but not identical drug could be the reason for the inconsistent outcomes.
Given the importance of Sost/sclerostin in the regulation of bone mass, we sought to 
determine whether the mechanism behind the increased bone formation in our experimental 
model involved changes in the expression of this protein. We found that sclerostin protein 
levels in bone were not affected by mefloquine treatment, suggesting that increased bone 
formation in mefloquine-treated mice is not due to downregulation of sclerostin levels. The 
mechanism of the increased bone formation with mefloquine warrants further investigation.
In summary, we show for the first time that mefloquine administration increases cancellous 
bone formation and volume in the vertebra and has beneficial effects on cortical bone 
mechanical properties in old mice. Our studies bring to light a potent pharmacological agent 
able to reverse at least partially the deleterious consequences of aging in bone.
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Highlights
• Aging is accompanied by imbalanced bone remodeling, elevated osteocyte 
apoptosis, and low bone mass/strength and new effective therapies are needed.
• Mefloquine effect was tested in young 3.5-month-old and old 21-month-old 
mice.
• Mefloquine increases vertebral cancellous bone formation and volume and 
has beneficial effects on cortical bone mechanical properties in old mice.
• Mefloquine is a potent pharmacological agent able to reverse at least partially 
the deleterious consequences of aging in bone.
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Fig. 1. Deleterious effect of aging on bone mass is partially reversed by mefloquine 
administration
(A) Cancellous bone microarchitecture analysis in L4 vertebra was assessed by μCT in 
mefloquine-treated young and old mice (n=6–10). Representative 3D images of cancellous 
bone in vertebra are shown. Bars represent mean ± s.d., #p<0.05 versus vehicle-treated 
young mice; *p<0.05 versus vehicle treated mice at the same age, by two-way ANOVA. All 
scale bars indicate 500μm.
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Fig. 2. Mefloquine administration reverses the decrease in bone formation induced by aging
(A) MAR, MS/BS, and BFR/BS were measure in unstained sections of lumbar vertebra 
(n=7–10). (B) N.Ob/BS and Ob.S/BS were scored in lumbar vertebra stained with von 
Kossa/McNeal (n=7–10). (C) N.Oc/BS, Oc.S/BS, and ES/BS were scored in lumbar vertebra 
stained for TRAPase/Toluidine blue (n=7–8) in young and old mice. Bars represent mean ± 
s.d., #p<0.05 versus vehicle-treated young mice; *p<0.05 versus vehicle treated mice at the 
same age, by two-way ANOVA. Representative images from lumbar vertebra sections for 
the corresponding analysis are shown (red arrows; osteoblasts and black arrows; osteoclasts). 
All scale bars indicate 50μm.
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Fig. 3. Administration of mefloquine has minimal effects on cortical bone geometry
Cortical bone geometry in the femoral mid-diaphysis was assessed by μCT (n=6–10) in 
young and old mice. Representative cross-section images of femoral mid-diaphysis are 
shown. Bars represent mean ± s.d., #p<0.05 versus vehicle-treated young mice; *p<0.05 
versus vehicle treated mice at the same age, by two-way ANOVA. All scale bars indicate 
500μm.
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Fig. 4. Mefloquine-treated young, but not old mice exhibit changes in histomorphometric 
parameters in cortical bone
(A) MAR, MS/BS, and BFR/BS were measured in unstained sections of femoral mid-
diaphysis (n=6–9). (B) N.Oc/BS, Oc.S/BS, and ES/BS were measured in cross-section of 
femoral mid-diaphysis stained for TRAPase (n=7–10). Representative images from 
osteoclasts on the bone surface (arrow, magenta) are shown. (C) Markers of bone resorption 
and formation were measured in serum from young and old mice treated with vehicle or 
mefloquine (n=6–10). Bars represent mean ± s.d., #p<0.05 versus vehicle-treated young 
mice; *p<0.05 versus vehicle treated mice at the same age, by two-way ANOVA. All scale 
bars indicate 50μm.
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Fig. 5. Increased serum bone resorption markers in young and old mice, and osteoclast 
differentiation in vitro induced by mefloquine
(A) Osteoclast number and (B) genes associated with osteoclast differentiation in cultures of 
non-adherent bone marrow cells treated with M-CSF and sRANKL, measured by qPCR and 
corrected by GAPDH (n=4). Representative images of in vitro generated osteoclasts are 
shown. Scale bars indicate 10μm. (C) ATP levels were measured in osteoclast lysates 
(intracellular ATP, n=3) after 7 days of differentiation using a luciferin-luciferase kit. Mature 
osteoclasts treated with vehicle or 1mM mefloquine for 24h were stained using 100μM 
quinacrine and visualized under fluorescence microscope (n=3). Scale bars indicate 100μm. 
Bars represent mean ± s.d. *p<0.05 versus vehicle treated group, by t-test.
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Fig. 6. Mefloquine administration does not affect sclerostin levels or osteocyte apoptosis in young 
or old mice
(A) Sost mRNA was measured in mefloquine-treated young and old mice in tibia (n=8–10). 
(B) sclerostin protein levels were measured by ELISA in L5 vertebra lysates (n=8–10). (C) 
Osteocyte numbers were measured in cortical bone of the femur and cancellous bone of the 
L3 vertebra (n=8–10). (D) Apoptotic osteocytes (active caspase-3-positive) and empty 
lacunae were enumerated in the femoral mid-diaphysis of young and old mice (n=5–9). 
Representative immunostaining image with a typical active caspase-3-positive (black arrow, 
brown) and viable osteocyte (white arrow, blue-green) is shown. (E) Genes associated with 
apoptosis were measured in tibiae without bone marrow cells at 3.5 and 21 months of age by 
qPCR and corrected by GAPDH (n=6–10).
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